Korsana Biosciences, a biotechnology startup focused on Alzheimer’s treatments, has announced a significant financial boost of $175 million to enhance its portfolio aimed at neurodegenerative diseases. The company is centered on KRSA-028, an innovative antibody designed to target and reduce the accumulation of amyloid beta, a protein linked to Alzheimer’s.
Established in 2024 with a $25 million seed investment, Korsana is also developing two additional unnamed programs for neurodegenerative conditions. The company’s Series A funding round last September, which received $150 million from various investors including Wellington Management and Sanofi Ventures, underscores its potential in the biotech field.
Korsana aims to provide a more effective treatment option compared to existing therapies, which often present serious side effects and limited efficacy. The company plans to present proof of concept data for KRSA-028 by the end of 2027. Korsana is led by Jonathan Violin, who emphasizes the need for improved patient options in Alzheimer’s care.